Next Article in Journal
On the Shoulders of a Giant: Contributions of Thomas Grogan, MD to Hematopathology
Next Article in Special Issue
Immunotherapy with Antibodies in Multiple Myeloma: Monoclonals, Bispecifics, and Immunoconjugates
Previous Article in Journal
Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 2
Previous Article in Special Issue
Why Immunotherapy Fails in Multiple Myeloma
Review

Decades of Progress in Allogeneic Stem Cell Transplantation for Multiple Myeloma

1
Division of Hematology and Medical Oncology, NYU Grossman School of Medicine, Perlmutter Cancer Center, NYU Langone Health, New York, NY 10012, USA
2
Department of Molecular Biotechnology and Health Sciences, University of Torino, 40138 Torino, Italy
3
IRCCS Azienda Ospedaliero Universitaria di Bologna, 40138 Bologna, Italy
4
Stem Cell Transplant Center, AOU Citta’ della Salute e della Scienza, 40138 Turin, Italy
*
Author to whom correspondence should be addressed.
Academic Editor: Nicolaus Kröger
Received: 11 January 2021 / Revised: 14 February 2021 / Accepted: 15 February 2021 / Published: 20 February 2021
Allogeneic hematopoietic cell transplantation in multiple myeloma has evolved over the decades. Myeloablative regimens have been replaced by the reduced intensity and non-myeloablative conditionings to reduce treatment-related toxicity and mortality while sparing graft-vs.-myeloma effects. Newer agents with potent anti-myeloma activity are not mutually exclusive and the combination with an allograft may improve long-term outcomes in this incurable disease especially in high-risk patients. Allografting may also be a platform for other promising new cell therapies such as CAR T-cells, NK-, and CAR NK-cells. These studies are warranted in the context of clinical trials. This review highlights the progress that has been made over the decades and possible future roles of allografting in the treatment landscape of multiple myeloma View Full-Text
Keywords: allogeneic transplantation; myeloablative; non-myeloablative; multiple myeloma; new drugs; CAR T allogeneic transplantation; myeloablative; non-myeloablative; multiple myeloma; new drugs; CAR T
Show Figures

Figure 1

MDPI and ACS Style

Bruno, B.; Lia, G.; Bonifazi, F.; Giaccone, L. Decades of Progress in Allogeneic Stem Cell Transplantation for Multiple Myeloma. Hemato 2021, 2, 89-102. https://0-doi-org.brum.beds.ac.uk/10.3390/hemato2010005

AMA Style

Bruno B, Lia G, Bonifazi F, Giaccone L. Decades of Progress in Allogeneic Stem Cell Transplantation for Multiple Myeloma. Hemato. 2021; 2(1):89-102. https://0-doi-org.brum.beds.ac.uk/10.3390/hemato2010005

Chicago/Turabian Style

Bruno, Benedetto, Giuseppe Lia, Francesca Bonifazi, and Luisa Giaccone. 2021. "Decades of Progress in Allogeneic Stem Cell Transplantation for Multiple Myeloma" Hemato 2, no. 1: 89-102. https://0-doi-org.brum.beds.ac.uk/10.3390/hemato2010005

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop